Free Trial
NASDAQ:KURA

Kura Oncology (KURA) Stock Price, News & Analysis

Kura Oncology logo
$5.91 +0.10 (+1.72%)
Closing price 07/3/2025 03:35 PM Eastern
Extended Trading
$5.91 0.00 (0.00%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Kura Oncology Stock (NASDAQ:KURA)

Key Stats

Today's Range
$5.76
$5.88
50-Day Range
$5.55
$6.92
52-Week Range
$5.41
$23.48
Volume
781,540 shs
Average Volume
1.25 million shs
Market Capitalization
$511.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.50
Consensus Rating
Moderate Buy

Company Overview

Kura Oncology Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

KURA MarketRank™: 

Kura Oncology scored higher than 91% of companies evaluated by MarketBeat, and ranked 283rd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kura Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Kura Oncology has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Kura Oncology's stock forecast and price target.
  • Earnings Growth

    Earnings for Kura Oncology are expected to grow in the coming year, from ($2.44) to ($1.72) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kura Oncology is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kura Oncology is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kura Oncology has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Kura Oncology's valuation and earnings.
  • Percentage of Shares Shorted

    9.75% of the float of Kura Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Kura Oncology has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Kura Oncology has recently decreased by 5.50%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Kura Oncology does not currently pay a dividend.

  • Dividend Growth

    Kura Oncology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.75% of the float of Kura Oncology has been sold short.
  • Short Interest Ratio / Days to Cover

    Kura Oncology has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in Kura Oncology has recently decreased by 5.50%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Kura Oncology has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Kura Oncology this week, compared to 6 articles on an average week.
  • Search Interest

    Only 7 people have searched for KURA on MarketBeat in the last 30 days. This is a decrease of -30% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Kura Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Kura Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,076.00 in company stock.

  • Percentage Held by Insiders

    Only 6.40% of the stock of Kura Oncology is held by insiders.

  • Read more about Kura Oncology's insider trading history.
Receive KURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

KURA Stock News Headlines

Post-Halving = Profit Season (Here’s How to Win It)
It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.
See More Headlines

KURA Stock Analysis - Frequently Asked Questions

Kura Oncology's stock was trading at $8.71 at the start of the year. Since then, KURA stock has decreased by 32.1% and is now trading at $5.91.

Kura Oncology, Inc. (NASDAQ:KURA) released its quarterly earnings results on Thursday, May, 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.15. The business earned $14.11 million during the quarter, compared to analysts' expectations of $39.08 million.
Read the conference call transcript
.

Kura Oncology's stock reverse split before market open on Friday, October 18th 2024.The 1-35 reverse split was announced on Monday, October 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Shares of KURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kura Oncology investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and Walmart (WMT).

Company Calendar

Last Earnings
5/01/2025
Today
7/04/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KURA
Fax
N/A
Employees
130
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.50
High Stock Price Target
$40.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+314.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
14 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$173.98 million
Pretax Margin
-264.22%

Debt

Sales & Book Value

Annual Sales
$53.88 million
Price / Cash Flow
N/A
Book Value
$5.32 per share
Price / Book
1.11

Miscellaneous

Free Float
81,034,000
Market Cap
$511.63 million
Optionable
Optionable
Beta
0.40

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:KURA) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners